The claim is too broad
A safety guide
Stem cell clinic red flags: when to slow down before you pay.
A red flag is not a verdict. It is a reason to slow down — to ask for specifics, to take the paperwork home, and to notice whether the answers stay specific too.
Some clinics offering regenerative-medicine treatments do the work carefully — with a real diagnosis, a named product, a written follow-up plan, and honest framing of what the evidence does and does not say. Some are selling hope faster than evidence. The difference usually shows up in the language: a specific product instead of vague “stem cells,” a measured outcome instead of a miracle promise, a written follow-up plan instead of sales pressure.1
This page is the safety companion to the rest of the site. It does not assume every clinic is bad, and it is not a list of things to be afraid of. It is a structured way to recognize patterns that deserve more scrutiny, in language you can use on the phone or in the consult room.
Red flags are patterns, not proof.
A single red flag is not, on its own, evidence of fraud. Some careful clinics use a phrase or two that, in isolation, would look like a warning sign — and then go on to back it up with specifics. What matters is whether the specifics arrive.
- One red flag is a prompt. Ask for the specific product, the specific evidence, the specific oversight. A careful clinic will answer.
- Several together should change your pace. If the language is broad, the product is vague, and the oversight is hand-waved, this is no longer a one-question consult.
- Vague answers are information. The absence of a specific answer to a specific question tells you something about the offering — and is not a personal failure of the clinician.
- The goal is friction, not fear. A short pause before a big decision is reasonable. Pressure to skip that pause is itself a signal.
A quick pattern map.
Most warning signs in regenerative-medicine marketing fall into five rough buckets. The map below is a quick scan; the full red flags follow underneath.
The product is too vague
The evidence is too thin
The oversight is missing
The sales process is too pressured
Twelve red flags, with what to ask instead.
Each red flag below has four parts: the pattern, why it matters, what to ask in its place, and when to slow down or walk away. Reading them in order is fine; if you arrived from a specific worry, the pattern map above will point you to the right one.
01
“Stem cells will regrow your cartilage” / “reverse bone-on-bone.”
Why it matters
Structural regrowth is a much higher bar than reducing pain or improving function. Where trials of regenerative products show benefit at all, the benefit is usually in patient-felt outcomes — pain, stiffness, function — not visible tissue regrowth on a scan.1
What to ask instead
What patient-felt outcome has been shown to improve in randomized trials of this exact product? Not what someone hopes for — what was measured.
When to slow down
Walk away if every claim is structural regeneration and none of the evidence is patient-felt.
02
One product offered for many unrelated conditions — arthritis, neurological disease, autoimmune disease, fertility, anti-aging.
Why it matters
Evidence is condition-specific. A treatment supported in one indication rarely generalizes to others, and clinicians who study this carefully are usually willing to say so.2
What to ask instead
What randomized trial supports this exact product for my exact condition?
When to slow down
Slow down if the marketing covers four or more unrelated indications. Walk away if no indication-specific evidence can be named for any of them.
03
Exosomes sold as “the next generation of stem cells,” or as approved.
Why it matters
Exosomes are signaling vesicles released by cells. They are not cells. No exosome product is FDA-approved in the United States, and the FDA has issued specific safety communications about unapproved exosome marketing.1
What to ask instead
What source cell are these from, who manufactures them, what quality testing runs per batch, and which regulator — if any — has reviewed this product?
When to slow down
Walk away if exosomes are described as approved without a named product and a named regulator that actually approved it.
04
“Your own cells, so there is no risk.”
Why it matters
Autologous origin — using your own tissue — establishes neither safety nor effectiveness. Published case series document severe complications, including the well-known 2017 report of bilateral vision loss after autologous fat-derived cells were injected far from their source tissue.6
What to ask instead
What complications have been reported with this product or procedure in the medical literature, and how do you track outcomes at this clinic?
When to slow down
Slow down if “no risk” is the answer. Walk away if the clinic claims to have never seen a complication.
05
No exact product name — only “stem cells,” “regenerative cells,” or a brand phrase.
Why it matters
Evidence belongs to specific products. Without a name — and a manufacturer or processing lab — none of the harder questions about evidence, oversight, or safety can be answered.
What to ask instead
What is the product called, and who manufactures or processes it?
When to slow down
Walk away if the clinic will not put the product name and source in writing.
06
Treatment offered without a diagnosis — based on symptoms, self-report, or a phone screening.
Why it matters
Regenerative-medicine procedures should be tied to a specific condition. A treatment without a diagnosis is a treatment without a target.
What to ask instead
What examination, imaging, or workup confirms I am a candidate for this specific procedure?
When to slow down
Walk away if no diagnostic workup precedes the procedure, or if the consult is structured to book before any examination.
07
“Published studies” or “backed by science” — but no specific paper.
Why it matters
A real published study has a journal, a year, a sample size, and a result. Generic appeals to “the research” do not.2
What to ask instead
Can you name one specific peer-reviewed study, for this exact product, in my exact condition?
When to slow down
Slow down if the citation can’t be produced in the consult. Walk away if it still can’t be produced afterward.
08
“Used internationally,” with no local regulator, hospital, or ethics board named.
Why it matters
Countries regulate cell-based products very differently. “Legal in this country” is not the same as “reviewed for your condition.” Foreign authorization can be meaningful — but only when it is attached to a specific regulator, a specific product, and a specific indication.2
What to ask instead
Which national regulator, hospital, ethics board, ministry pathway, or trial registry oversees this exact product for this exact condition?
When to slow down
Slow down if the answer is geographic. Walk away if no specific oversight body can be named.
09
No follow-up schedule. No written complication plan. No coordination with your home doctor.
Why it matters
Regenerative-medicine procedures can have delayed effects, and travel makes complication management harder. A careful clinic plans for after the appointment, not just for it.
What to ask instead
What is the follow-up schedule at 30, 90, and 180 days, and who manages complications if they show up after I go home?
When to slow down
Walk away if no written follow-up plan is provided before any deposit.
10
Package pricing. “Today only.” Refusal to quote without a deposit.
Why it matters
Pricing pressure is a sales tactic, not a clinical reason. A medical decision should hold up if you take the documents home and read them slowly.
What to ask instead
Can I take the written quote and the refund policy home, and book later if I decide to proceed?
When to slow down
Walk away if the clinic resists any of this — especially if the deadline is tied to a discount.
11
Before-and-after photos, or testimonial videos, used as the main evidence.
Why it matters
Individual cases cannot stand in for trial evidence. Photos and videos are marketing artifacts, not measured outcomes.5
What to ask instead
Beyond patient stories, what randomized or controlled study supports this product for my condition?
When to slow down
Slow down if photos are the only evidence offered. Walk away if a quoted success rate has no sample size and no source.
12
“FDA does not apply here” used to end the conversation.
Why it matters
FDA is one lens; its absence is not, by itself, a problem. The problem is when no other oversight is named in its place. Honest answers describe what does apply — a hospital pathway, a trial registry, a national regulator, an ethics board — and what that oversight does and does not cover.1
What to ask instead
If FDA does not apply, what does — and how would I verify it independently?
When to slow down
Walk away if the answer is some version of “no regulator applies to this.”
What a better answer sounds like.
A red flag goes away when the clinic answers with specifics. The contrast below is not a script — it is what specific sounds like next to vague. A clinician doing this work carefully will tend to sound closer to the right-hand column on most questions.
Instead of vague
“Stem cells regenerate your joints.”
A better answer sounds like
“This is PRP prepared with a named kit, studied for pain and function in mild-to-moderate knee osteoarthritis. We measure pain and function at 3 and 6 months. We do not promise tissue regrowth.”
Instead of vague
“Used internationally.”
A better answer sounds like
“This product is permitted under a hospital-exemption pathway for this specific indication. Here is what that pathway requires, what it does not require, and how to verify it with the local regulator.”
Instead of vague
“Your own cells, so it is risk-free.”
A better answer sounds like
“The documented complications for this procedure include the following. We screen patients with these criteria, and we follow up at 30, 90, and 180 days. Here is the clinician who manages complications after you go home.”
When to pause, when to get a second opinion, when to walk away.
This is editorial guidance, not medical or legal advice. Use it as a sense-of-pace check, not as a rulebook. Most consults sit in the first group; a few earn the second; the third is for the cases where the answers are not just vague but actively pressured.
Pause and ask more if
- One phrase in the consult is vague.
- The cited study is hard to verify on the spot.
- The pricing is unclear or arrives in pieces.
- The follow-up plan exists but isn’t in writing yet.
Get a second opinion if
- The diagnosis itself is unclear.
- The procedure is invasive or involves anesthesia.
- You would travel — especially internationally — for it.
- Donor cells are involved.
- The delivery is intravenous.
- Repeated treatments are recommended.
Walk away if
- A cure or guaranteed reversal is promised.
- The product cannot be named or written down.
- No written follow-up or complication plan is offered.
- The clinic uses pressure tactics or deadline discounts.
- The oversight question is refused or hand-waved away.
What this is not.
- Not medical advice. Nothing here is tailored to your case. The job of this page is to help you notice patterns and ask sharper questions, not to prescribe.
- Not a clinic recommendation. We do not name specific clinics to use or to avoid.
- Not a claim that every clinic is bad. Some clinicians do this work carefully, with real oversight, in the U.S. and abroad. These patterns are how to see the careful work more clearly.
- Not an FDA-only page. FDA status matters for U.S. readers, but it is not the only oversight that matters, and its absence does not automatically condemn a foreign clinic. The question is always whether some meaningful oversight applies.
Quick answers to the questions readers usually arrive with.
Four short answers, two or three sentences each. The longer answers live in the sections above.
- What are the biggest red flags at a stem cell clinic?
- The patterns that come up most often are very broad claims (regrowing cartilage, reversing aging), a product that is never named, evidence that is gestured at but never cited, oversight that is hand-waved away, and pressure to deposit before you can take the paperwork home. Any one of these is a reason to ask more questions. Several together is a reason to slow the whole conversation down.
- Does one red flag mean a clinic is a scam?
- No. A single red flag is a prompt to ask for specifics, not proof of fraud. Careful clinics sometimes use a phrase that, in isolation, sounds like a warning sign — and then back it up with a named product, a specific study, and a written follow-up plan. What matters is whether the specifics arrive when you ask.
- Is “not FDA-approved” always a red flag?
- Not on its own. FDA status matters for U.S. readers, but its absence is not, by itself, a problem. The problem is when no other oversight is named in its place. Outside the United States, the honest question is which national regulator, hospital pathway, ethics board, ministry pathway, or trial registry oversees this exact product for this exact condition — and whether you can verify that independently.
- What should I do if a clinic says stem cells can regrow cartilage or reverse aging?
- Treat broad regeneration claims as the moment to ask for specifics. What is the exact product? What randomized trial supports it for your exact condition? What patient-felt outcome was measured, and over what follow-up? If the answers stay at the level of “the body heals itself” without naming a product or a study, that is information about the offering — and a reason to slow down before paying.
Where to go from here.
If you want to keep reading, these pages go deeper on the questions to bring to a consult, what is actually in the syringe, how to read the evidence, and what the whole thing is likely to cost.
Questions to ask a stem cell clinic before you pay →
What is actually in the syringe — a product field guide →
How CellDecide weighs evidence →
How CellDecide reads a paper and writes a page →
Sources & footnotes
- U.S. Food & Drug Administration. “Important Patient and Consumer Information About Regenerative Medicine Therapies.” fda.gov · the FDA’s patient-facing guidance on what is approved, what is investigational, and what kinds of marketing claims have prompted enforcement. Verified 2026-05-14. ↩
- International Society for Stem Cell Research. “ISSCR Guidelines for Stem Cell Research and Clinical Translation” and the patient-facing “A Closer Look at Stem Cell Treatments handbook.” isscr.org / closerlookatstemcells.org · the Clinical Translation chapter sets out responsible-translation norms, including condition-specific evidence and the limits of autologous-origin and foreign-availability reasoning. Verified 2026-05-14. ↩
- U.S. National Library of Medicine. “ClinicalTrials.gov public registry.” clinicaltrials.gov · the registry referenced when this page invokes “a real trial.” A listing reflects registration, not endorsement, approval, or proof of efficacy. Verified 2026-05-14. ↩
- U.S. Food & Drug Administration. “Warning Letters — FDA enforcement database.” fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters · public archive of warning letters issued to companies and clinics, including regenerative-medicine and stem-cell enforcement actions, used here only as background context for the patterns described in body prose. Verified 2026-05-14. ↩
- Cochrane Library and related systematic reviews of regenerative-medicine interventions. cochranelibrary.com· the standard for the kind of measured, condition-specific evidence the “published studies” and “before-and-after photos” red flags are asking the clinic to produce. Verified 2026-05-14. ↩
- Kuriyan AE, Albini TA, Townsend JH, et al. “Vision Loss after Intravitreal Injection of Autologous ‘Stem Cells’ for AMD.” New England Journal of Medicine2017; 376:1047–1053 · documented case series of severe vision loss after autologous adipose-derived cells were injected far from their tissue of origin. Cited under the “your own cells, so it’s risk-free” red flag. Verified 2026-05-14. ↩